Pfiz­er pub­lish­es clin­i­cal tri­al di­ver­si­ty da­ta from past decade, show­ing there's much work to be done

The pan­dem­ic turned a harsh spot­light on a his­toric lack of di­ver­si­ty in the bio­phar­ma in­dus­try. Now, in an ef­fort to fos­ter trans­paren­cy, Pfiz­er has pub­lished di­ver­si­ty da­ta from its clin­i­cal tri­als go­ing back 10 years, show­ing there’s much work to be done.

Be­tween 2011 and 2020, Black or African Amer­i­can par­tic­i­pants made up 14.3% of 212 tri­als for which da­ta on race was col­lect­ed, ac­cord­ing to Pfiz­er. To put that in per­spec­tive, Black Amer­i­cans rep­re­sent about 13.4% of the US pop­u­la­tion. But when bro­ken down by tri­al, on­ly about half of Pfiz­er’s stud­ies (56.1%) sur­passed cen­sus lev­els for Black par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER